-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has been recognized as a provincial demonstration enterprise for technological innovation.
Category:
Time:2023-01-07
On January 6, the Hebei Provincial Department of Industry and Information Technology released the list of provincial-level demonstration enterprises for technological innovation for 2022. Among them, 36 companies—including Hebei Guangxiang Pharmaceutical Co., Ltd.—were recognized by the Provincial Department of Industry and Information Technology as provincial-level demonstration enterprises for technological innovation in 2022.
It is reported that the selection of demonstration enterprises for technological innovation in Hebei Province primarily evaluates enterprises from multiple aspects, including innovation investment, talent incentives, innovation collaboration, innovation team building, development of innovation infrastructure, accumulation and reserves of technological expertise, outputs of technological innovation, and benefits derived from technological innovation. The certification process is conducted in accordance with requirements set forth in documents such as the "Administrative Measures for the Certification of Demonstration Enterprises for Technological Innovation in Hebei Province," and involves procedures including initial review and recommendation by the industrial and information technology bureaus of various cities, preliminary document review, expert evaluation, on-site inspections, and public announcement online.
Guangxiang Pharmaceutical serves as the origin for Shijiazhuang Four Pharmaceutical Group’s strategy of building an integrated “API + Finished Dosage Form” business model, accelerating industrial transformation, and strengthening and extending the supply chain. Since last year, Guangxiang Pharmaceutical has continuously refined its innovation mechanisms, intensified efforts to build a robust science and technology innovation system, and significantly increased investment in research and development capabilities. The company has been relentlessly tackling key core technologies—such as independent R&D of specialty APIs and high-end APIs, as well as API synthesis—and steadily speeding up the commercialization of research projects and the translation of scientific findings into practical applications, thereby enhancing the resilience of its innovation, industrial, and supply chains. Meanwhile, leveraging research approaches like "listing challenges and appointing leaders" and "flexible recruitment of expert talent," Guangxiang Pharmaceutical has successively established collaborations with prestigious research institutions including Tsinghua University and Tianjin University. These partnerships have enabled the company to forge an independently innovative system centered on industry-academia-research-application integration, technological platform development, and new product R&D, thus creating a new engine of momentum for its innovative growth.
In 2022, Guangxiang Pharmaceutical successfully achieved the commercialization of eight specialty active pharmaceutical ingredients (APIs), including pentoxifylline, levonidazole, and ornidazole. These technological innovations have provided strong support for the company’s high-quality development. Guided by innovation-driven development, Guangxiang Pharmaceutical has successively been recognized as a High-Tech Enterprise, a Provincial Enterprise Technology Center, a Provincial Technology Innovation Center, a Provincial Engineering Research Center for Continuous Synthesis of APIs via Micro-Reactions, a Postdoctoral Research Workstation, a Provincial Science and Technology-based Small and Medium-sized Enterprise, a Provincial Demonstration Enterprise for Specialization, Precision, and Innovation, a Provincial Industrial Enterprise R&D Institution (Grade A), and a Provincial Green Factory.
Keywords:
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code